research articles ↓

In a recent email to Rosacea News, Dr. Eduardo Pérez, VP of Operations at Signum Biosciences has confirmed that SIG990 is undergoing preclinical safety/toxicology testing as required by the FDA before clinical trials can commence. You can see this confirmed at the company’s web site: Pharmaceutical Development Pipeline.

Signum Biosciences has several molecules under development, SIG990 is their lead candidate for rosacea.
Anti-Redness Efficacy of SIG0990
In …

A company called Signum Biosciences is developing a new product to target rosacea. Based on a technology that they call G-protein Modulators, GPMs are said to “restore signalling imbalances in the cell”. A first generation product called Arazine is soon to become available and a second generation of products are to target rosacea, psoriasis and eczema.

According to Signum Bioscience’s Development Pipeline, SIG990 is in …

Brady Barrows has announced that the RRDi has published the Journal of the Rosacea Research & Development Institute: Volume 1 Number 1, 2010. The journal has been produced by volunteer rosacea sufferers and consists of `articles by …

The name Albert Kligman has been associated with dermatology for a very long time. Perhaps best known for his work with the acne treatment Retin-A, Dr. Kligman is credited with more than 1,500 publications on acne, rosacea, eczema, contact dermatitis and skin aging. According to Albert M. Kligman, 93, dermatology researcher, Dr. Kligman cowrote 14 books, beginning with Textbook on Dermatology, published by …

Professor Frank Powell has created something quite valuable for rosacea sufferers and their physicians, an authorative and approachable medical text.

If you want to get hold of the best rosacea book you can buy, then this is the book for you. Find out why I think so in the detailed review below….